Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
gptkb:radio_station
|
| gptkbp:advocacy |
required before treatment
|
| gptkbp:affects |
potential for late toxicity
|
| gptkbp:approves |
gptkb:2003
gptkb:FDA |
| gptkbp:associated_with |
immunosuppression
|
| gptkbp:availability |
limited in some regions
|
| gptkbp:can_be_combined_with |
chemotherapy
|
| gptkbp:class |
radioimmunotherapy agents
|
| gptkbp:clinical_trial |
Phase II
Phase III continues to evolve. ongoing for new indications NCT00003612 |
| gptkbp:clinical_use |
rituximab resistant cases
|
| gptkbp:collaborations |
with academic institutions
|
| gptkbp:contains |
Iodine-131
|
| gptkbp:contraindication |
severe hypersensitivity to tositumomab
|
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
injectable solution
|
| gptkbp:drug_interactions |
may interact with other immunosuppressants
|
| gptkbp:duration |
single dose
|
| gptkbp:eligibility |
specific criteria for use
|
| gptkbp:events |
monitoring blood counts
|
| gptkbp:feedback |
mixed reviews
|
| gptkbp:financial_support |
available through manufacturer
|
| gptkbp:funding |
supported by government grants
|
| gptkbp:healthcare |
sterile, preservative-free solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bexxar
|
| gptkbp:indication |
relapsed or refractory non-Hodgkin lymphoma
|
| gptkbp:ingredients |
tositumomab
|
| gptkbp:is_effective_against |
improves overall survival
|
| gptkbp:is_monitored_by |
thyroid function tests
necessary for adverse effects requires imaging studies |
| gptkbp:marketed_as |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:mechanism_of_action |
delivers radiation to cancer cells
targeting CD20 antigen |
| gptkbp:patient_education |
importance of follow-up
|
| gptkbp:patient_population |
adults
|
| gptkbp:patient_response |
variable
|
| gptkbp:pharmacokinetics |
long half-life
|
| gptkbp:price |
expensive treatment option
|
| gptkbp:produces |
iodine-131 labeled
|
| gptkbp:provides_guidance_on |
outpatient
included in lymphoma treatment protocols |
| gptkbp:regulatory_compliance |
prescription only
|
| gptkbp:research |
Bexxar vs. Rituximab
|
| gptkbp:research_focus |
lymphoma treatment advancements
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
hypothyroidism
infusion reactions secondary malignancies myelosuppression |
| gptkbp:storage |
refrigerated
|
| gptkbp:targeted_antigen |
CD20
|
| gptkbp:treatment |
improved quality of life
remission rates reduce tumor burden requires pre-treatment assessment varies by lymphoma subtype |
| gptkbp:treatment_limitations |
not suitable for all patients
|
| gptkbp:used_for |
gptkb:non-Hodgkin_lymphoma
treatment of non-Hodgkin lymphoma |
| gptkbp:bfsParent |
gptkb:Idec_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|